Communiqués ImmuCell Corporation

Actions

ICCC

US4525253062

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 08/09/2026			Varia. 5j.	Varia. 1 janv.
9,840 ^USD	-0,61 %		-0,81 %	+60,00 %

14/08	Transcript : ImmuCell Corporation, Q2 2026 Earnings Call, Aug 14, 2026
13/08	ImmuCell Corporation publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

13/08	ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026	AQ
06/08	ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026	AQ
09/07	ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results	AQ
14/05	ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026	AQ
07/05	ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026	AQ
22/04	ImmuCell : Corporate Presentation (Investor Relations April 2026 Final)	PU
13/04	ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors	AQ
08/04	ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results	AQ
18/03	ImmuCell : 03-18-26 – ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board	PU
18/03	ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board	AQ
04/03	ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025	AQ
18/02	ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025	AQ
08/01	ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025	AQ
07/01	ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus	AQ
24/12	ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®	AQ
13/11	ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025	AQ
06/11	ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025	AQ
04/11	ImmuCell Announces Onboarding of New CEO and Related Management Changes	AQ
07/10/25	ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025	AQ
29/09/25	ImmuCell Announces Selection of its Next President and CEO	AQ
14/08/25	ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025	AQ
12/08/25	ImmuCell Announces Bank Debt Refinancing	AQ
07/08/25	ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2025	AQ
09/07/25	ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025	AQ
25/06/25	ImmuCell Embarks on CEO Succession Planning Process	AQ